March 2026 in “Lithuanian University of Health Sciences” Finasteride, dutasteride, and oral minoxidil are effective for treating hair loss, with spironolactone as an option for women.
Early combination therapy can effectively regrow hair in frontal fibrosing alopecia.
February 2026 in “Revista Eletrônica Polidisciplinar Voos.” A balanced approach using dutasteride and Serenoa repens can improve hair transplant success by protecting follicles and minimizing side effects.
February 2026 in “American Journal of Clinical Dermatology” Spironolactone is effective for treating female hair loss, with new treatments like clascoterone showing promise.
February 2026 in “NeuroSci” Finasteride and dutasteride may cause depression and anxiety, especially in younger men.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Adapalene, Diosmin, and Azelastine may effectively treat onchocerciasis.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Adapalene, Diosmin, and Azelastine may effectively treat onchocerciasis.
January 2026 in “Dermatologic Surgery” Injectable therapy, especially with dutasteride, may help with hair loss, but more research is needed.
January 2026 in “Ciencia Latina Revista Científica Multidisciplinar” Exosome-based therapy successfully restored hair in a 14-year-old with difficult-to-treat alopecia areata.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
January 2026 in “GSC Biological and Pharmaceutical Sciences” Adapalene, Diosmin, and Azelastine could be repurposed to treat onchocerciasis.
January 2026 in “Ciencia Latina Revista Científica Multidisciplinar” Exosomes helped regrow hair in a 14-year-old with difficult-to-treat alopecia.
January 2026 in “Journal of Dermatological Treatment” Oral finasteride may cause more sexual side effects than expected, possibly due to negative publicity and reporting bias.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Dutasteride 0.5 mg/day is the best treatment for male pattern baldness.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Dutasteride 0.5 mg/day is the best treatment for male pattern baldness.
January 2026 in “Yonsei Medical Journal” Finasteride and dutasteride have little effect on Type 2 Diabetes risk.
January 2026 in “International Society of Hair Restoration Surgery” Tattoo machine-assisted drug delivery may improve hair growth in androgenetic alopecia.
January 2026 in “Dermatologic Therapy” Microneedling may improve hair loss treatments by enhancing drug delivery and hair growth.
December 2025 in “Instituto Politécnico do Porto” Patients with mood disorders using 5α-reductase inhibitors may have a higher risk of suicidal thoughts.
December 2025 in “Open Repository of the University of Porto (University of Porto)” Pharmacists play a crucial role in improving patient outcomes through personalized care and staying updated with scientific advancements.
December 2025 in “Actas Dermo-Sifiliográficas” Use a combination of oral dutasteride, topical treatments, and hydroxychloroquine to manage frontal fibrosing alopecia.
December 2025 in “Medicine - Programa de Formación Médica Continuada Acreditado” Recent advancements in hair loss treatments include new therapies and insights for different types of alopecia.
Alopesi tedavisinde ilaçlar saç büyümesini teşvik eder ve yeni yaklaşımlar umut vaat eder.
November 2025 in “International Journal of Apllied Mathematics” Numerical methods help analyze alopecia drugs' properties effectively.
October 2025 in “Open Repository of the University of Porto (University of Porto)” Dutasteride is more effective than finasteride for hair growth, and sublingual apomorphine quickly improves Parkinson's symptoms.
September 2025 in “PubMed” Prevent persistent hair loss after chemotherapy with scalp cooling and early minoxidil use.
September 2025 in “Cosmetics” Genetic profiling can improve androgenetic alopecia treatment by predicting drug response and minimizing side effects.
August 2025 in “The Journal of Sexual Medicine” Finasteride, dutasteride, and silodosin have the highest risk for causing sexual dysfunction.
August 2025 in “ACS Omega” New compounds show promise as nonsteroidal treatments for hair loss.